Impel Pharmaceuticals Inc. (NASDAQ:IMPL) Q3 2022 Results Conference Call November 14, 2022 8:30 AM ET

Company Participants

John Leaman - Chief Financial & Business Officer

Adrian Adams - Chairman & CEO

Leonard Paolillo - Chief Commercial Officer

Conference Call Participants

Ken Cacciatore - Cowen

Operator

Good morning, ladies and gentlemen, and welcome to Impel Pharmaceuticals Third Quarter 2022 Earnings and Business Update Conference Call. At this time, all participants are in a listen-only mode. Later in this call a question-and-answer session will be conducted and instruction on how to participate will be given at that time. As a reminder, today's conference call is being recorded.

And now, I would like to turn the conference over to Impel's Chief Financial and Business Officer, Dr. John Leaman. Please go ahead.

John Leaman

Thank you, Chris, and good morning, everyone. We are delighted that you could join us today for Impel Pharmaceuticals quarterly earnings conference call to review our third quarter 2022 commercial and financial results, as well as to provide a general business update.

Joining me from Impel this morning is Adrian Adams, Impel's Chairman of the Board and Chief Executive Officer; and Len Paolillo, Chief Commercial Officer. Before we begin, I would like to remind everyone that we have a slide presentation to accompany our conference call this morning, which can be viewed at our website at www.impelpharma.com. If you are listening to this call on your telephone, you may access a synchronized slide deck on our website by choosing the link on our webcast page that says click here to listen.

Moving to slide two, forward-looking statements. I'd like to remind you that during the call, the company will be making forward-looking statements that are subject to risks and uncertainties that may cause actual results to differ from the results discussed in the forward-looking statements.

With that, I will turn the call over to Adrian Adams. Adrian?

Adrian Adams

Thank you, John, and good morning, everyone, and thank you all for joining us. I am pleased, as always, to update you on the commercial and corporate progress we have made in quarter three and year-to-date 2022. The agenda for today's call can be seen on our next slide, slide number three. During this call, we will provide a prescription performance update for Trudhesa, in addition to covering ongoing prescriber, market access and patient dynamic data for the third quarter and year-to-date 2022. We will then briefly review our financial performance in addition to providing a status update on the market and clinical development opportunity with INP105 for the treatment of autism. I will then present an overall summary and an outlook for the business going forward before opening the call up for your valued questions. .